Drug Pricing – How Pharma Can Ease the Burden
In this POV, market access gurus Mike Motto, Glen Davis, and Peter Weissberg, discuss recent Trump administration action on drug pricing, the likelihood of further action before the 2020 election, and how pharma manufacturers can provide affordable options for more Americans.
Industry Group Will Create New Standards to Protect Ad Practices and Consumers
As the demand for more privacy protections continues, the ad industry moves to create new standards that protect digital advertising practices, including targeting and messaging, while also maintaining consumer privacy.
Shoppable Services: Price Transparency Era’s First Real Business Bellwether
Many pharma executive and marketing leaders actively monitor the pricing transparency conversation in search of the meaningful insights that can truly impact their business performance. And while much public attention has been paid to items such as “drug costs in TV commercials” and “CEO testimony before Congress,” little evidence exists that they have actually moved […]
EVP Wendy Blackburn: 5 Options for Managing the DTC Transparency Debacle
Drug pricing is a hot button issue, including the pricing transparency battle, and it’s not going away anytime soon. On July 8, U.S. District Court Judge Amit Mehta ruled that the Department of Health and Human Services had overstepped its authority in requiring pricing disclosures, stating, “That policy very well could be an effective tool […]
Complying With Colorado’s New Drug Price Transparency Law
This POV describes Colorado House Bill 19-1131 and how it could affect pharma marketers. The bill requires that any one-to-one communications between pharmaceutical representatives (or anyone communicating on their behalf) and prescribers must include written information about the wholesale cost of a drug, as well as the names of at least three generic equivalents. The law goes into effect on August 2, 2019.